The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Recap by typeshit. Full story at Medical Xpress.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
He points to a November 2026 study he says suggests semaglutide and other GLP-1 drugs may help beyond diabetes and obesity in people with schizophrenia.
Novo also reported 25% average weight loss in women on CagriSema in a post-hoc trial analysis, while BMO flagged Ozempic losing US share.
WebMD notes that eating less on a GLP-1 can mean missing some nutrients, and suggests asking your doctor about nutrition while on the drug.
Loading…